Ozkan, SerhatElibol, BulentOzkaynak, Sehur SibelCakmur, RaifAkbostanci, Muhittin CenkHanagasi, HasmetDogu, Okan2024-06-262024-06-262021-12-011301-062Xhttps://doi.org/10.4274/tnd.2021.06706https://hdl.handle.net/11452/42439Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications during Parkinson's disease, which could be administered as an intermittent or continuous infusion. Although apomorphine treatment has been shown to be effective on motor fluctuations and dyskinesias, there is no sufficient consensus regarding the administration of apomorphine test or infusion, and the management of the treatment. In this review, our aim is to create a "treatment management guideline," which includes recommendations for the use of apomorphine in the clinical practice, and to discuss the problems encountered in both intermittent and continuous infusion applications, in the light of the literature.eninfo:eu-repo/semantics/closedAccessTerm follow-upSubcutaneous apomorphineDouble-blindUltrasound treatmentInfusionMotorEfficacyReceptorApomorphineParkinson's diseaseTreatmentScience & technologyLife sciences & biomedicineClinical neurologyNeurosciences & neurologyReview00074071560000135836527410.4274/tnd.2021.06706